
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
Meet Pharm Exec?s 2009 Emerging Leaders?27 industry pioneers under age 45 who are bringing new ideas to life - 09 emerging leaders






